

STEFAN J. KLAUBER
DAVID A. JACKSON
BARBARA L. RENDA
RAYMOND M. SPEER*
PAUL F. FEHLNER
MICHAEL D. DAVIS*
JOSEPH M. HOMA
LORI B. COHEN*

COUNSEL

JACK MATALON
LAWRENCE D. MANDEL

KLAUBER & JACKSON
ATTORNEYS AT LAW
CONTINENTAL PLAZA
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

PATENT, TRADEMARK AND
COPYRIGHT CAUSES
(201) 487-5800
FACSIMILE: (201) 343-1684
INTERNET: 626-1210@MCIMAIL.COM

August 7, 1996

*BAR OTHER THAN N.J.
Assistant Commissioner of Patents
Washington, D.C. 20231

Attention: Application Processing Division
Special Processing and Correspondence Branch


Re: U.S. Patent Application

Applicant(s): Jeffrey M. Friedman et al.
Serial No.: 08/599,974
Filed: February 14, 1996
Title: DB, THE RECEPTOR FOR LEPTIN, NUCLEIC
ACIDS ENCODING THE RECEPTOR, AND USES
THEREOF
Docket No.: 600-1-162CP1

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231 on August 7, 1996.

Paul F. Fehlner, Ph.D. Reg. No. 35.135
(Name of Registered Representative)


(Signature and Date)

SUBMISSION OF MISSING PARTS OF APPLICATION
UNDER 37 CFR 1.53(d)

Sir:

Responsive to the Notice of File Missing Parts of Application dated May 7, 1996 under 37 CFR 1.53(d)(copy enclosed), Applicants submit herewith the following:

1. Three (3) counterparts of a combined Declaration and Power of Attorney forms making reference to the above-identified application, and in compliance with 37 CFR 1.63;

2. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.
3. A copy of the Sequence Listing in computer readable form (ASCII text), submitted on a 3½" floppy disk compatible with IBM format.
4. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 - 1.825.
5. A copy of the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
6. A Petition for a Two-Month Extension of Time under 37 CFR 1.136(b).
7. A check in the amount of \$ 3,482.00, covering the following:
 - (a) Filing Fee under 37 CFR 1.16 (including multiple dependent claims) 2,972.00;
 - (b) Surcharge under 37 CFR 1.16 130.00;
 - (c) Fee for Two-Month Extension of time under 37 CFR 1.17(b) 380.00.

The time set for this response, including the two month extension requested herein, is August 7, 1996.

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,



Paul F. Fehlner, Ph.D.
Attorney for Applicant(s)
Registration No. 35,135

PFF/rf
Enclosures



APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
08/599,974	02/14/96	FRIEDMAN	J 600-1-162CP1

PAUL F. FEHLNER
KLAUFER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK NJ 07601

0252/0507

DATE MAILED: 0000

05/07/96

NOTICE TO FILE MISSING PARTS OF APPLICATION
FILING DATE GRANTED

An Application Number and Filing Date have been assigned to this application. However, the items indicated below are missing. The required items and fees identified below must be timely submitted **ALONG WITH THE PAYMENT OF A SURCHARGE** for items 1 and 3-6 only of \$ 130 for large entities or \$ 15 for small entities who have filed a verified statement claiming such status. The surcharge is set forth in 37 CFR 1.16(e).

If all required items on this form are filed within the period set below, the total amount owed by applicant as a ☒ large entity, ☐ small entity (verified statement filed), is \$ 3192.

Applicant is given **ONE MONTH FROM THE DATE OF THIS LETTER, OR TWO MONTHS FROM THE FILING DATE** of this application, **WHICHEVER IS LATER**, within which to file all required items and pay any fees required above to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

1. ☒ The statutory basic filing fee is: ☐ missing ☐ insufficient. Applicant as a ☒ large entity ☐ small entity, must submit \$ 750 to complete the basic filing fee.
2. ☒ Additional claim fees of \$ 2222 as a ☐ large entity, ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
3. ☐ The oath or declaration:
☐ is missing.
☐ does not cover items omitted at time of execution.

An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date is required.
4. ☐ The oath or declaration does not identify the application to which it applies. An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
5. ☒ The signature(s) to the oath or declaration is/are: ☐ missing; ☐ by a person other than the inventor or a person qualified under 37 CFR 1.42, 1.43, or 1.47. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
6. ☐ The signature of the following joint inventor(s) is missing from the oath or declaration:

_____. An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date, is required.
7. ☐ The application was filed in a language other than English. Applicant must file a verified English translation of the application and a fee of \$ _____ under 37 CFR 1.17(k), unless this fee has already been paid.
8. ☐ A \$ _____ processing fee is required since your check was returned without payment. (37 CFR 1.21(m)).
9. ☐ Your filing receipt was mailed in error because your check was returned without payment.
10. ☒ The application does not comply with the Sequence Rules. See attached Notice to Comply with Sequence Rules 37 CFR 1.821-1.825.
11. ☐ Other.

Direct the response and Special Pro. **notice MUST be** ATTORNEY'S/APPLICANTS CC.

Application No.: 08/599976

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE